Wanquet, A., Crocchiolo, R., Furst, S., Granata, A., Faucher, C., Devillier, R., Harbi, S., Lemarie, C., Calmels, B., Vey, N., Weiller, P. J., Chabannon, C., Castagna, L., Blaise, D., & El-Cheikh, J. (n.d.). the efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. Leukemia & lymphoma, 57(10), 2315–2320. http://access.bl.uk/ark:/81055/vdc_100034959453.0x000038